Washington, DC – October 15, 2024 – The Vapor Technology Association (VTA) filed with the Supreme Court of the United States (SCOTUS) an amicus brief against the FDA and in support of Respondents in United States Food & Drug Administration v. Wages & White Lion Investments, dba Triton Distribution et al.
Unlike the amicus briefs we filed in this on-going litigation which focused on the FDA’s wrongdoings and the adverse economic impact of failing to hold the FDA to legal account, this brief focused on the recent dramatic change in SCOTUS jurisprudence in Loper Bright v. Raimondo which dramatically altered the manner in which federal courts evaluate whether agencies – like the FDA – have acted within the confines of the law by assessing the best reading of the statute.
VTA’s amicus brief supports Respondents arguments and encourages SCOTUS to look skeptically – through the prism of Loper – at the FDA’s arguments and its post-hoc justifications for its actions. VTA’s amicus brief highlights three key points:
- LOPER REQUIRES THAT FDA’S DENIAL ORDERS BE SET ASIDE BECAUSE THEY VIOLATE THE BEST READING OF THE TOBACCO CONTROL ACT.
- THE BEST READING OF THE TOBACCO CONTROL ACT DOES NOT ALLOW FDA TO ISSUE DENIAL ORDERS BASED ON THE POST-HOC COMPARATIVE EFFICACY TEST.
- FDA PROCESS FOR REVIEWING PMTAS WAS HEAVILY CRITICIZED BY AN INDEPENDENT TOBACCO EXPERT PANEL WHICH CALLED OUT THE FDA’S FAILURE TO CONSISTENTLY APPLY THE APPH TEST.
VTA’s full amicus brief is available HERE.